Therapeutic Asset Ratings

165 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Pembrolizumab Meningioma	Essen Biotech	P1/2	CC (47)
TIL Meningioma	Essen Biotech	P1/2	CC (47)
TIL Glioblastoma	Essen Biotech	P1/2	CC (46)
Anti-Cd19/Cd22 Car-T Cells Central Nervous System Lymphoma	Essen Biotech	P1/2	CC (45)
cd123-cd33 ccar t cells Acute Myeloid Leukemia	Essen Biotech	P1/2	CC (45)
cd22 car-transduced t cells Primary Central Nervous System Lymphoma	Essen Biotech	P1/2	CC (45)
cd5/cd7 car-t T-cell Acute Lymphoblastic Leukemia	Essen Biotech	P1/2	CC (45)
Dual-Target Antigen-Selected Car-Nk Acute Myeloid Leukemia	Essen Biotech	P1/2	CC (45)
Dual-Target Antigen-Selected Car-Nk Cutaneous Melanoma	Essen Biotech	P1/2	CC (45)
Dual-Target Antigen-Selected Car-Nk Non-Hodgkin Lymphoma	Essen Biotech	P1/2	CC (45)
EBNK-001 Cutaneous Melanoma	Essen Biotech	P1/2	CC (45)
EBNK-001 Malignant Pancreatic Neoplasm	Essen Biotech	P1/2	CC (45)
Eb-Select Single-Target Car-Nk Cells Acute Myeloid Leukemia	Essen Biotech	P1/2	CC (45)
Eb-Select Single-Target Car-Nk Cells Cutaneous Melanoma	Essen Biotech	P1/2	CC (45)
Eb-Select Single-Target Car-Nk Cells Non-Hodgkin Lymphoma	Essen Biotech	P1/2	CC (45)
Fludarabine Exocrine Pancreatic Carcinoma	Essen Biotech	P1/2	CC (45)
gpc3 cd146 car-t cells Ovarian Carcinoma	Essen Biotech	P1/2	CC (45)
il-15 Cutaneous Melanoma	Essen Biotech	P1/2	CC (45)
il-15 Malignant Pancreatic Neoplasm	Essen Biotech	P1/2	CC (45)
Mesothelin-Directed Car-T Cells Pancreatic Carcinoma	Essen Biotech	P1/2	CC (45)
TIL Brain Cancer	Essen Biotech	P1/2	CC (45)
TIL Rectal Cancer	Essen Biotech	P1/2	CC (45)
TIL Colon Carcinoma	Essen Biotech	P1/2	CC (44)
Anti-Cd33 Cart Acute Myeloid Leukemia	Essen Biotech	P1/2	CC (43)
Bcma/Gprc5D Car-T Cells Sarcoma	Essen Biotech	P1/2	CC (43)

Showing 101 to 125 of 165 assets

PreviousPage 5 of 7Next